MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Cebranopadol

CAS No. : 863513-91-1

MCE 站：Cebranopadol

产品活性：Cebranopadol 是NOP 和 opioid receptor 激动剂，作用于人NOP，MOP，KOP 和δ-阿片肽(DOP)受体，K_i/EC₅₀ 分别为 0.9 nM/13 nM，0.7 nM/1.2 nM，2.6 nM/17 nM，18 nM/110 nM。

研究领域：GPCR/G Protein  |  Neuronal Signaling

作用靶点：Opioid Receptor

In Vitro: Cebranopadol binds with high affinity (subnanomolar to nanomolar range) to nociceptin/orphanin FQ peptide (NOP) and opioid receptors, with K_i of 1±0.5 nM, 2.4±1.2 nM, and 64±11 nM for rat NOP, mu-opioid peptide (MOP) receptor, and kappa-opioid peptide (KOP) receptor, and with K_i of 0.9±0.2 nM, 0.7±0.3 nM, and 2.6±1.4 nM for Rat NOP, MOP, and KOP receptor.

In Vivo: Cebranopadol exhibits highly potent and efficacious antinociceptive and antihypersensitive effects in several rat models of acute and chronic pain (tail-flick, rheumatoid arthritis, bone cancer, spinal nerve ligation, diabetic neuropathy) with ED₅₀ values of 0.5-5.6 μg/kg after intravenous and 25.1 μg/kg after oral administration. In comparison with selective MOP receptor agonists, cebranopadol is more potent in models of chronic neuropathic than acute nociceptive pain. Cebranopadol’s duration of action is long (up to 7 hours after intravenous 12 μg/kg; >9 hours after oral 55 μg/kg in the rat tail-flick test). The antihypersensitive activity of cebranopadol in the spinal nerve ligation model is partially reversed by pretreatment with the selective NOP receptor antagonist J-113397 or the opioid receptor antagonist naloxone, indicating that both NOP and opioid receptor agonism are involved in this activity. Development of analgesic tolerance in the chronic constriction injury model is clearly delayed compared with that from an equianalgesic dose of morphine (complete tolerance on day 26 versus day 11, respectively). Unlike morphine, cebranopadol did not disrupt motor coordination and respiration at doses within and exceeding the analgesic dose range. Cebranopadol, by its combination of agonism at NOP and opioid receptors, affords highly potent and efficacious analgesia in various pain models with a favorable side effect profile.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Neuronal Signaling Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Diabetes Related Compound Library  |  Orally Active Compound Library  |  Neurotransmitter Receptor Compound Library  |  DAMGO  |  Naltrindole hydrochloride  |  Sinomenine hydrochloride  |  JDTic dihydrochloride  |  Matrine  |  Loperamide hydrochloride  |  Nalfurafine hydrochloride  |  Nociceptin  |  JTC-801  |  [Leu5]-Enkephalin  |  Norbinaltorphimine dihydrochloride  |  Tyr-Gly-Gly-Phe-Met-OH  |  Endomorphin 1  |  CTAP TFA  |  Endomorphin 2 TFA  |  Noscapine  |  LY2795050  |  β-Endorphin, human  |  N-Desmethylclozapine  |  BAN ORL 24  |  Dynorphin A  |  Alvimopan dihydrate  |  Asimadoline  |  Dynorphin A (1-10) (TFA)  |  Corydaline  |  Porcine dynorphin A(1-13)  |  Dermorphin  |  Dynorphin B (1-13) (TFA)

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。